HUTCHMED (China) Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HMDCF research report →
Companywww.hutch-med.com
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments.
- CEO
- Chig Fung Cheng
- IPO
- 2014
- Employees
- 1,811
- HQ
- Hong Kong, HK
Price Chart
Valuation
- Market Cap
- $1.86B
- P/E
- 4.57
- P/S
- 4.71
- P/B
- 1.70
- EV/EBITDA
- -858.01
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 18.62%
- Op Margin
- -2.64%
- Net Margin
- 104.77%
- ROE
- 41.38%
- ROIC
- -0.69%
Growth & Income
- Revenue
- $549.32M · -12.83%
- Net Income
- $457.58M · 1112.82%
- EPS
- $0.53 · 1101.81%
- Op Income
- $-54,661,741
- FCF YoY
- -352.64%
Performance & Tape
- 52W High
- $3.81
- 52W Low
- $2.16
- 50D MA
- $2.81
- 200D MA
- $3.23
- Beta
- 0.38
- Avg Volume
- 29
Get TickerSpark's AI analysis on HMDCF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our HMDCF Coverage
We haven't published any research on HMDCF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HMDCF Report →